Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on RSS
Research ArticleArticle

Effect of Atorvastatin on Inflammation and Modification of Vascular Risk Factors in Rheumatoid Arthritis

AMAL M. EL-BARBARY, MANAL S. HUSSEIN, ELSAYED M. RAGEH, HALA E. HAMOUDA, AYMAN A. WAGIH and RAGHDA G. ISMAIL
The Journal of Rheumatology February 2011, 38 (2) 229-235; DOI: https://doi.org/10.3899/jrheum.100582
AMAL M. EL-BARBARY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ml_barbary@yahoo.com
MANAL S. HUSSEIN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ELSAYED M. RAGEH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HALA E. HAMOUDA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AYMAN A. WAGIH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RAGHDA G. ISMAIL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

Objective. To investigate the effect of atorvastatin therapy on inflammation, disease activity, endothelial dysfunction, and arterial stiffness in patients with rheumatoid arthritis (RA).

Methods. This study included 30 patients with early RA, randomly divided into 2 groups. Group 1 (n = 15) received methotrexate (MTX; 0.2 mg/kg/week; mean (15.5 ± SD 1.3) plus prednisone (10 mg/day). Group 2 (n = 15) received MTX and prednisone with the same previous doses plus atorvastatin therapy (40 mg/day). Ten healthy individuals of similar age and sex served as controls. Disease activity, lipid profile, serum malondialdehyde (MDA), tumor necrosis factor-α (TNF-α), resistin, adiponectin, and brachial artery flow-mediated dilation (FMD) were measured before and after 6 months of treatment.

Results. Atorvastatin combined with MTX therapy significantly reduced serum total cholesterol, low-density lipoprotein cholesterol, and triglycerides, and increased high-density lipoprotein cholesterol (p < 0.001). Disease activity variables, serum MDA, TNF-α, resistin, adiponectin, and FMD were significantly improved by the drug combinations (p < 0.001).

Conclusion. Atorvastatin therapy in patients with RA reduced disease activity and conventional and novel vascular risk factors that promote the atheromatous lesion. Therapy was also associated with concomitant improvement in endothelial function.

  • RHEUMATOID ARTHRITIS
  • ATORVASTATIN
  • ADIPOKINES
  • BRACHIAL ARTERY FLOW-MEDIATED DILATION

Rheumatoid arthritis (RA) is a chronic progressive autoimmune disorder characterized by symmetric erosive synovitis and sometimes showing multisystem involvement. The longterm outcome is characterized by significant morbidity, loss of functional capacity, and increased mortality. This disease affects about 1% of the general population worldwide1.

There is intense interest in mechanisms whereby low-grade inflammation could interact with conventional and novel vascular risk factors to promote the atheromatous lesion. Patients with RA manifested by persistent high levels of inflammation are at greater risk of developing cardiovascular disease2.

White adipose tissue is now considered to be a dynamic endocrine organ that secretes a number of factors that are increasingly recognized to contribute to systemic and vascular inflammation3. Tumor necrosis factor-α (TNF-α) is one adipokine involved in systemic inflammation and is a member of a group of cytokines that stimulate the acute-phase reaction. The primary role of TNF-α is in regulation of immune cells. TNF is also able to induce apoptotic cell death, to induce inflammation, and to inhibit tumorigenesis4.

Resistin is a recently discovered cysteine-rich adipokine of 108 amino acid and 12.5 kDa that has emerged during this decade as a promising inflammatory marker in various diseases in humans by means of its secretion in substantial quantities by mononuclear cells5. It is synthesized either from adipocytes or from immune cells, and exerts a proinflammatory profile in a variety of different experimental settings. Resistin has been shown to increase transcriptional events, leading to increased expression of several proinflammatory cytokines including (but not limited to) interleukin 1 (IL-1), IL-6, IL-12, and TNF-α6.

Adiponectin has been identified as one of the “adipocytokines” that are derived only from adipose tissue, and that are abundantly present in circulating blood. Adiponectin has protective actions in the initiation and progression of atherosclerosis through its antiinflammatory and antiatherogenic effects7.

It is well established that the antioxidant system is impaired in RA and reactive oxygen species (ROS) cannot be removed effectively. Because of impairment, it seems that patients with RA are exposed to lipid peroxidation, which is one of the indicators of oxidative stress8. Investigations also support the oxidative-stress hypothesis of atherosclerosis. Oxidative stress is the unifying mechanism for many cardiovascular disease (CVD) risk factors, which additionally supports its central role in CVD9.

Vascular endothelial injury is the primary event in atherosclerosis, and has been associated with endothelial dysfunction10. This may be determined as an impaired ability of the artery to dilate in response to physical and chemical stimuli due to reduced bioavailability of nitric oxide (NO)11. Endothelial function can be noninvasively determined by postocclusion flow-mediated vasodilatation (FMD) of the brachial artery using high-sensitivity brachial ultrasonography12.

Atorvastatin (ATV) is a member of the drug class known as statins, which are 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, which have demonstrated benefit in the primary and secondary prevention of cardiovascular disease by promoting reduction in plasma concentrations of low-density lipoprotein (LDL) cholesterol13. Some of the clinical benefits of statin therapy are the pleiotropic effects that are believed to include antiinflammatory actions, the reversal of endothelial dysfunction by prevention of LDL oxidation, and the increase of NO bioavailability14.

We investigated the effect of atorvastatin therapy on disease activity, endothelial dysfunction, and arterial stiffness in patients with RA.

MATERIALS AND METHODS

Thirty patients with RA were selected from the Outpatient Clinic of the Physical Medicine and Rheumatology Department, Tanta University Hospitals; all fulfilled the 1987 American College of Rheumatology revised criteria for diagnosis of RA15. All patients had disease duration of less than 1 year with no prior use of disease-modifying antirheumatic drugs (DMARD) and/or systemic steroids. In addition, 10 healthy volunteers matched for age and sex were recruited as controls.

Exclusion criteria

Subjects excluded from the study were those with conditions that affect the lipid profile, endothelial dysfunction, and arterial stiffness, such as diabetes mellitus, hypothyroidism, liver or kidney disease, Cushing’s syndrome, obesity (body mass index > 30), current smokers, history of familial dyslipidemia, myocardial infarction during the last 6 months, and any malignancy or seizure. In addition, patients receiving medications affecting lipid metabolism such as lipid-lowering drugs, oral prednisolone > 10 mg/day, beta blockers, oral contraceptives, estrogen, progestin, thyroxin, and vitamin E were excluded.

Study design

Patients with RA were randomly divided into 2 groups and the treatment was given in unblinded fashion. Group 1 (n = 15) received methotrexate (MTX; 0.2 mg/kg/week; mean total dose/wk 15.5 ± SD 1.3) plus prednisone (10 mg/day); Group 2 (n = 15) received MTX and prednisone with the same dose as Group 1 plus atorvastatin therapy (40 mg/day). The dose of MTX remained stable during the study whereas the dose of prednisone was tapered according to the patient’s clinical response. But this procedure was forbidden within 4 weeks of clinical and laboratory assessment.

Approval was obtained from the Local Research Ethics Committee, and written informed consent was obtained from each participant.

Disease activity was assessed by the Disease Activity Score for 28 joints (DAS28)16. Components of DAS28 are erythrocyte sedimentation rate (ESR), patient-assessed global score (0–100), swollen and tender joint counts (0–28); whereas the clinical response was evaluated according to European League Against Rheumatism (EULAR) criteria to calculate the response in DAS28, that is, comparing the DAS28 from one patient at 2 different timepoints17.

Laboratory investigations

Overnight fasting venous blood samples were taken from controls and patients before and after the recommended lines of treatment, transferred slowly into a dry sterile centrifuge tube, then centrifuged as soon as possible at 2000 g for 10 min at 4°C, and aliquots of serum were immediately stored at −70°C until the analysis.

Routine laboratory investigations included complete blood count, ESR, serum C-reactive protein (CRP), and lipid profile. Specific investigations included (1) serum TNF-α level, determined using Quantikine Human TNF-α ELISA kits (Roche Diagnostics GmbH, Mannheim, Germany)18; (2) serum resistin concentration, by a sandwich ELISA using the Max Human resistin ELISA kit19; (3) serum adiponectin concentration, using the Quantikine Human Adiponectin ELISA kit (R&D Systems, Bad Nauheim, Germany)20; and (4) spectrophotometric determination of serum malondialdehyde (MDA) as a marker for oxidative stress21.

We recorded adverse events throughout the study. We performed hematology and biochemical screening for liver function, creatine kinase, and renal function at baseline and at 6 months.

Ultrasound examination of brachial artery FMD

Subjects underwent noninvasive examination of endothelium-dependent vasodilation (FMD) and endothelium-independent vasodilation (nitroglycerine-mediated dilation; NMD) of the brachial artery on the nondominant arm, according to the International Brachial Artery Reactivity Task Force guidelines12. FMD was expressed as the relative increase in brachial artery diameter using hyperemia, and defined as (posthyperemic diameter – basal diameter)/basal diameter × 100. The maximum FMD and NMD diameters were calculated as the average of the 3 consecutive measurements and the percentage changes in the diameters compared with baseline resting diameter, and expressed as percentage diameter variation. FMD was carried out blinded to the treatment given.

After screening, study visits were scheduled for 0 and 6 months.

Statistical analysis

Data were analyzed using SPSS software (version 11, SPSS Inc., Chicago, IL, USA). Baseline characteristics are presented as mean ± standard deviation for the continuous variables, and as frequency and percentage for discrete variables. Baseline comparisons between groups were conducted using ANOVA. Student’s t test was used for paired data to examine within-group differences. ANCOVA was used for comparisons of the effect of drugs between groups. Correlation between variables was examined using Pearson’s correlation coefficient. Multiple linear regression analysis was performed to investigate independent associations of several biochemical and inflammatory variables with changes in FMD. FMD changes between the end of the study and baseline were used as a dependent variable. The changes in serum lipids and biochemical variables that could affect the FMD were included as independent variables.

RESULTS

A total of 30 patients with active RA completed the study. The demographic variables and biochemical and hemodynamic characteristics of patients and controls at entry are shown in Table 1. They were 25 women and 5 men with a mean age of 53.7 ± 15.4 years in Group 1 and 54.8 ± 14.7 years in Group 2. There were no significant differences in age, sex, and mean body mass index values between patients and controls. Patients with early RA exhibited mild dyslipidemia characterized by significantly higher baseline total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and triglycerides (TG) compared to controls. In addition, high-density lipoprotein cholesterol (HDL-C) levels were significantly lower compared to controls. As a consequence, the atherogenic ratio of TC/HDL-C as well as that of LDL-C/HDL-C was significantly higher in RA patients compared to controls.

View this table:
  • View inline
  • View popup
Table 1.

Baseline demographic, biochemical, and hemodynamic characteristics of subjects with rheumatoid arthritis and controls. Values represent mean ± standard deviation.

All biochemical markers including serum MDA, resistin, adiponectin, and TNF-α were significantly higher in RA patients than in controls. Endothelial function was determined by postocclusion FMD of the brachial artery, which was significantly lower in patients compared to controls.

Table 2 shows the effect of treatment on lipid profile, disease activity indicators, adipokines, and hemodynamic measures after 6 months of each drug therapy. There was a significant decrease in the disease activity variables. The reduction was more pronounced with atorvastatin therapy (Group 2) than with MTX therapy (Group 1). There were significant increases of serum levels of TC and HDL-C compared to baseline values before treatment, without significant change in the serum levels of LDL-C and TG, in Group 1 after treatment. However, there were significant reductions in TC, LDL-C, and TG levels with significant increase in HDL-C in Group 2 after treatment. Importantly, the atherogenic ratios TC/HDL-C and LDL-C/HDL-C were significantly reduced after treatment in Group 2, moreso than in Group 1.

View this table:
  • View inline
  • View popup
Table 2.

Effect of treatment on disease activity, lipid profile, adipokines, and hemodynamics. Values represent mean ± standard deviation.

There were significant decreases in biochemical markers including serum MDA, resistin, and TNF-α in both groups after treatment; the reduction was more pronounced in Group 2 than in Group 1. By contrast, serum levels of adiponectin were significantly increased and their levels were higher in Group 2 compared with Group 1 after treatment. In Group 2, FMD was significantly increased after treatment (from 3.72 ± 2.22% to 6.74 ± 3.78%) with no significant change in Group 1.

Moderate or good DAS28 responses (EULAR criteria) were achieved in 10 of 15 (66.6%) patients in Group 2 compared with 3 of 15 (20%) patients in Group 1 after 6 months of treatment.

As for the correlation matrix in all RA patients (n = 30), serum resistin and TNF-α were positively correlated with activity variables including DAS28, ESR, and CRP before and after treatment (p < 0.001). Adiponectin levels were positively correlated with these activity variables, serum resistin, and TNF-α before treatment (p < 0.001). However, adiponectin levels were negatively correlated with the same variables after treatment (p < 0.001). FMD was negatively correlated to LDL-C before and after treatment (p < 0.001). Moreover, we found no correlation between lipid profiles and serum MDA compared to inflammatory markers or disease activity.

We examined correlations with change over time in patients allocated to atorvastatin (Group 2); the reduction of LDL-C was found to correlate with the improvement of FMD (r = −0.45, p < 0.05). Moreover, there was significant positive correlation between the change in adiponectin levels and FMD (r = 0.64, p < 0.003). In addition, the change in adiponectin levels had a significant inverse correlation with the change in TNF-α (r = −0.77, p < 0.001), serum resistin (r = −0.70, p < 0.001), and CRP level (r = −0.45, p < 0.05).

Multiple linear regression showed that the change in FMD was statistically significantly associated with the change in LDL-C (B = 0.13, p = 0.032) and adiponectin levels (B = 0.09, p < 0.001).

Regarding steroid doses during the 6-month period after withdrawal of the baseline dose, 12 of 15 (80%) patients in the MTX group (Group 1) and 11 of 15 (73.3%) patients in the atorvastatin group (Group 2) received oral prednisone 5 to 10 mg/day at different frequencies. No patient received steroid within 4 weeks of clinical and laboratory assessment.

Atorvastatin was well tolerated in the study population. Adverse events (mild gastrointestinal upset) arose with similar frequency in patients who received combined atorvastatin and MTX (Group 2) compared to patients who received MTX only (Group 1). In particular, no significant liver function or muscle abnormality was detected in those given atorvastatin.

DISCUSSION

Our study revealed increased levels of TC, LDL-C, and TG and decreased levels of HDL-C in patients with early active RA. As a consequence, the atherogenic ratio of TC/HDL-C as well as that of LDL-C/HDL-C was significantly higher compared to controls. Moreover, there was no significant correlation between lipid profile and activity or laboratory variables. These changes are associated with an increased incidence of cardiovascular disease in the general population. The available literature on lipid profiles in RA is contradictory. There have been studies reporting increased, decreased, or similar levels for TC, LDL-C, and HDL-C in comparison to controls22,23,24,25,26,27. The discrepancies in the lipid values observed in the various studies might be due to differences in study populations and in disease activity.

After 6 months of MTX therapy (Group 1), a significant increase in serum HDL-C levels was observed that resulted in reduction of the atherogenic ratios TC/HDL-C and LDL-C/HDL-C. This improvement was associated with a reduction in disease activity and in the acute-phase reactants. These observations indicate that active disease with a stable inflammatory response expressed by a persistently elevated CRP may be responsible for the development of early atherosclerosis in RA. Georgiadis, et al28 documented effective suppression of disease activity at an early stage with MTX, and this was associated with a reduction in dyslipidemia and a decrease in mortality. Hadda, et al29 stated that DMARD control the inflammation, which leads to normalization of functions of circulating cytokines like TNF-α, IL-1ß, and IL-6, which alters the function of distant tissues, including the adipose tissue, skeletal muscle, liver, etc., which leads to dyslipidemia.

We have observed significant suppression of acute-phase variables and marked reduction in disease activity with atorvastatin therapy (Group 2) as compared with MTX therapy (Group 1). Moreover, atorvastatin substantially increased the HDL-C levels, with a reduction in LDL-C, TG levels, and atherogenic ratios; this provides a direct coronary heart disease-protective pathway in RA30. The mechanism of the effect of atorvastatin on the lipid profile was largely attributed to the ability of atorvastatin to impair cholesterol synthesis by inhibiting the enzyme HMG-CoA reductase, which is the rate-limiting step in cholesterol biosynthesis. This inhibition induces hepatocytes to increase their surface expression of LDL receptors, which promotes uptake and clearance of circulating LDL31,32,33.

We demonstrated that serum concentrations of MDA were significantly increased in patients with RA compared with control subjects; this is in agreement with other studies in which higher MDA levels have been reported in patients with RA, confirming the role of oxidative stress in the pathogenesis of RA34. On the other hand, Olivieri, et al35 reported no change in lipid peroxidation.

MDA levels showed a significant decrease in patients with RA in both groups studied, with a more significant reduction with atorvastatin therapy (Group 2). This is in agreement with findings from Akyol, et al36, who reported that MDA levels in the untreated patients were significantly higher than those of treated patients due to suppression of inflammatory conditions, which drive leukocytes into the affected joint, where they become activated to produce ROS.

The marked significant reduction in MDA levels with atorvastatin treatment in Group 2 may be attributed to the antioxidant-mediated effect of atorvastatin that results from inhibition of the mevalonate pathway, leading to reduction in the synthesis of important intermediates including isoprenoids that serve as lipid attachments for intracellular signaling molecules, in particular, inhibition of small GTPase-binding proteins (Rho, Rac, Ras, and G proteins). These proteins modulate a variety of cellular processes including signaling, differentiation, and proliferation37. Some of the antioxidant effects of atorvastatin may be due to its metabolites, such as hydroxyl metabolites, that have direct antioxidant effects. Atorvastatin improves and preserves the level of vitamins C and E and endogenous antioxidants such as reduced glutathione38. Moreover, atorvastatin treatment may play a role in protecting LDL-C and HDL-C from oxidation by increasing antioxidant activity of the HDL-associated enzyme and paraoxonase 139.

The results of our study showed that serum TNF-α and resistin levels were significantly increased in RA patients compared with controls. Also, their levels were positively correlated with disease activity variables. Previous studies observed increased resistin levels in synovial fluid from patients with RA40. These authors observed the association between synovial fluid resistin levels, disease activity, and acute-phase reactants, including CRP and IL-1Ra-antagonizing IL-1ß suggests that resistin may be a significant mediator in the inflammatory process of RA41.

In our study, TNF-α and resistin levels showed a significant decrease with MTX therapy (Group 1), but they were still higher than those of the control group. Their levels with atorvastatin therapy (Group 2) showed a more statistically significant decrease when compared to Group 1. Our study confirmed previous findings that TNF-α could induce resistin expression in human macrophages42. The inhibitory effect of atorvastatin on TNF-α-induced resistin expression provides additional evidence of a pleiotropic effect of statin42. Statin therapy may become another therapeutic strategy for controlling resistin-associated pathologic cardiovascular disease in humans43.

As for baseline serum levels of adiponectin, levels were significantly increased in RA patients compared to controls. Our results are in accord with those of Senolt, et al44 and Otero, et al45, who demonstrated significantly higher adiponectin levels in RA patients compared to healthy controls. Moreover, there was a significant positive correlation between adiponectin levels and activity scores, ESR, CRP, and serum TNF-α and resistin levels, in agreement with the results of Otero, et al45, who recorded the correlation between activity of RA and adiponectin levels. In contrast, Senolt, et al44 concluded that adiponectin levels were not related to disease activity in RA.

Serum levels of adiponectin showed more significant increases with atorvastatin therapy (Group 2) when compared to corresponding levels with MTX therapy (Group 1). Moreover, there was a significant negative correlation between the levels of adiponectin after treatment and activity variables. The changes in adiponectin levels had a significant positive correlation with changes in FMD and an inverse correlation with the changes in TNF-α, serum resistin, and CRP. This result is in agreement with data from Nakamura, et al46, who suggested that insulin-sensitizing and antiinflammatory effects of atorvastatin may be related to the increase in adiponectin levels. Further, increase in adiponectin levels may partially mediate the restoration of endothelial vasomotor function, after treatment with statin increased nitric oxide. By contrast, another study reported that simvastatin significantly decreased adiponectin levels and insulin sensitivity47. Bruun, et al48 showed that plasma TNF-α and IL-6 levels were negatively correlated with the plasma adiponectin level in humans. By contrast, another study reported that there was no correlation between the plasma TNF-α and adiponectin levels49.

We demonstrated that atorvastatin significantly improved endothelial function in RA to a level similar to that of healthy control subjects (an FMD > 4.5% is considered to be normal). The reduction of total LDL and increased adiponectin level was significantly correlated with the improvement of FMD, suggesting that these factors were related to the improvement in endothelial function. This result was in accord with findings of Tomas, et al50, who concluded that atorvastatin has a beneficial effect on lipid profile associated with an improvement in peripheral FMD, and its improvement is related to the levels of LDL. Mäki-Petäjä, et al51 have shown that both ezetimibe and simvastatin reduce inflammatory markers, disease activity, and endothelial function, and concomitantly arterial stiffness was improved by both drugs.

In summary, cholesterol-reducing therapies may be beneficial for patients with RA, because they are well tolerated, improve clinical outcome, and reduce cardiovascular risk.

  • Accepted for publication September 1, 2010.

REFERENCES

  1. 1.↵
    1. Theis KA,
    2. Helmick CG,
    3. Hootman JM
    . Arthritis burden and impact are greater among U.S. women than men: intervention opportunities. J Womens Health 2007;16:441–53.
    OpenUrlCrossRef
  2. 2.↵
    1. Sattar N,
    2. McCarey DW,
    3. Capell H,
    4. McInnes IB
    . Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003;108:2957–63.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Guzik TJ,
    2. Mangalat D,
    3. Korbut R
    . Adipocytokines — novel link between inflammation and vascular function? J Physiol Pharmacol 2006;57:505–28.
    OpenUrlPubMed
  4. 4.↵
    1. Locksley RM,
    2. Killeen N,
    3. Lenardo MJ
    . The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001;104:487–501.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Steppan CM,
    2. Bailey ST,
    3. Bhat S,
    4. Brown EJ,
    5. Banerjee RR,
    6. Wright CM,
    7. et al.
    The hormone resistin links obesity to diabetes. Nature 2001;409:307–12.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Silswal N,
    2. Singh AK,
    3. Aruna B,
    4. Mukhopadhyay S,
    5. Ghosh S,
    6. Ehtesham NZ
    . Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappa B-dependent pathway. Biochem Biophys Res Commun 2005;334:1092–101.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Blanco-Colio LM,
    2. Martín-Ventura JL,
    3. Gómez-Guerrero C,
    4. Masramon X,
    5. de Teresa Farsang C,
    6. Gaw A,
    7. et al.
    Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk. Eur J Pharmacol 2008;31:259–65.
    OpenUrl
  8. 8.↵
    1. Baskol G,
    2. Demir H,
    3. Baskol M,
    4. Kilic E,
    5. Ates F,
    6. Kocer D,
    7. et al.
    Assessment of paraoxonase 1 activity and malondialdehyde levels in patients with rheumatoid arthritis. Clin Biochem 2005;38:951–5.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Singh U,
    2. Jialal I
    . Oxidative stress and atherosclerosis. Pathophysiology 2006;13:129–42.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Celermajer DS,
    2. Sorensen KE,
    3. Gooch VM,
    4. Spiegelhalter DJ,
    5. Miller OI,
    6. Sullivan ID
    . Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111–5.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Blann AD
    . Endothelial cell activation, injury, damage and dysfunction: separate entities or mutual terms? Blood Coagula Fibrinolysis 2000;11:623–30.
    OpenUrlCrossRef
  12. 12.↵
    1. Corretti MC,
    2. Anderson TJ,
    3. Benjamin EJ,
    4. Celermajer D,
    5. Charbonneau F,
    6. Creager MA
    . Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002;39:257–65.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Shepherd J,
    2. Hunninghake DB,
    3. Barter P,
    4. Mckenney,
    5. Hutchinson E
    . Guidelines for lowering lipids to reduce coronary artery disease risk: A comparison of rosuvastatin with atorvastatin, pravastatin and simvastatin for achieving lipid lowering goals. Am J Cardiol 2003;91:11C–19C.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Vishal T,
    2. Bano G,
    3. Khajuria V,
    4. Parihar A,
    5. Gupta S
    . Pleiotropic effects of statins. Ind J Pharmacol 2003;37:77–85.
    OpenUrl
  15. 15.↵
    1. Arnett FC,
    2. Edworthy SM,
    3. Bloch DA,
    4. McShane DJ,
    5. Fries JF,
    6. Cooper NS,
    7. et al.
    The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Prevoo ML,
    2. van ’t Hof MA,
    3. Kuper HH,
    4. van Leeuwen MA,
    5. van de Putte LP,
    6. van Riel PL
    . Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44–8.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. van Gestel AM,
    2. Anderson JJ,
    3. van Riel PL,
    4. Boers M,
    5. Haagsma CJ,
    6. Rich B,
    7. et al.
    ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. J Rheumatol 1999;26:705–11.
    OpenUrlPubMed
  18. 18.↵
    1. Pinckard JK,
    2. Sheehan KCF,
    3. Schreiber RD
    . Ligand induced formation of p55 and p75 tumor necrosis factor receptor heterocomplexes on intact cells. J Biol Chem 1997;272:10784–9.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Chen D,
    2. Fang Q,
    3. Chai Y,
    4. Wang H,
    5. Huang H,
    6. Dong M
    . Serum resistin in gestational diabetes mellitus and early postpartum. Clin Endocrinol 2007;67:208–11.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Arita Y,
    2. Kihara S,
    3. Ouchi N,
    4. Takahashi M,
    5. Maeda K,
    6. Miyagawa J,
    7. et al.
    Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257:79–83.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Satoch K
    . Serum lipid peroxidation in cerebrovascular disorders determined by a new colorimetric method. Clin Chem Acta 1978;90:37–43.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Heldenberg D,
    2. Caspi D,
    3. Levtov O,
    4. Werbin B,
    5. Fishel B,
    6. Yaron M
    . Serum lipids and lipoprotein concentrations in women with rheumatoid arthritis. Clin Rheumatol 1983;2:387–91.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Lorber M,
    2. Aviram M,
    3. Linn S,
    4. Sharf Y,
    5. Brook JG
    . Hypocholesterolaemia and abnormal high-density lipoprotein in rheumatoid arthritis. Br J Rheumatol 1985;24:250–5.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Lakatos J,
    2. Harsagyi A
    . Serum total, HDL, LDL cholesterol and triglyceride levels in patients with rheumatoid arthritis. Clin Biochem 1988;21:93–6.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Kavanaugh A
    . Dyslipoproteinaemia in a subset of patients with rheumatoid arthritis. Ann Rheum Dis 1994;53:551–2.
    OpenUrlFREE Full Text
  26. 26.↵
    1. Asanuma Y,
    2. Kawai S,
    3. Aoshima H,
    4. Kaburaki J,
    5. Mizushima Y
    . Serum lipoprotein(a) and apolipoprotein(a) phenotypes in patients with rheumatoid arthritis. Arthritis Rheum 1999;42:443–7.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Georgiadis AN,
    2. Papavasiliou EC,
    3. Lourida ES,
    4. Alamanos Y,
    5. Kostara C,
    6. Tselepis AD,
    7. et al.
    Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment in a prospective, controlled study. Arthritis Res Ther 2006;8:R82.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Georgiadis AN,
    2. Voulgari PV,
    3. Argyropoulou MI,
    4. Alamanos Y,
    5. Elisaf M,
    6. Tselepis AD,
    7. et al.
    Early treatment reduces the cardiovascular risk factors in newly diagnosed rheumatoid arthritis patients. Semin Arthritis Rheum 2008;38:13–9.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Hadda V,
    2. Handa R,
    3. Aggarwal P,
    4. Lakshmy R,
    5. Kumar U,
    6. Pandey RM
    . Disease activity and lipids in rheumatoid arthritis: a prospective study. Ind J Rheumatol 2007;2:137–40.
    OpenUrlCrossRef
  30. 30.↵
    1. McCarey DW,
    2. McInnes IB,
    3. Madhok R,
    4. Hampson R,
    5. Scherbakova O,
    6. Ford I,
    7. et al.
    Trial of atorvastatin in rheumatoid arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004;363:2015–21.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Alegret M,
    2. Silvestre JS
    . Pleiotropic effects of statins and related pharmacological experimental approaches. Methods Find Exp Clin Pharmacol 2006;28:627.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Save V,
    2. Patil N,
    3. Moulik N,
    4. Rajadhyaksha G
    . Effect of atorvastatin on type 2 diabetic dyslipidaemia. J Cardiovasc Pharmacol Ther 2006;11:262–70.
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    1. Istvan ES,
    2. Deisenhofer J
    . Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001;292:1160–4.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    1. Seven A,
    2. Güzel S,
    3. Aslan M,
    4. Hamuryudan V
    . Lipid, protein, DNA oxidation and antioxidant status in rheumatoid arthritis. Clin Biochem 2008;41:538–43.
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Olivieri O,
    2. Girelli D,
    3. Trevisan MT,
    4. Bassi A,
    5. Zorzan P,
    6. Bambara LM,
    7. et al.
    Red blood cell susceptibility to lipid peroxidation, membrane lipid composition and antioxidant enzymes in patients with rheumatoid arthritis. J Rheumatol 1991;18:1263–4.
    OpenUrlPubMed
  36. 36.↵
    1. Akyol O,
    2. Isçi N,
    3. Temel I,
    4. Özgöçmen S,
    5. Uz E,
    6. Murat M,
    7. et al.
    The relationships between plasma and erythrocyte antioxidant enzymes and lipid peroxidation in patients with rheumatoid arthritis. Joint Bone Spine 2001;68:311–7.
    OpenUrl
  37. 37.↵
    1. Liao JK,
    2. Laufs U
    . Pleiotropic effects of statins. Ann Rev Pharmacol Toxicol 2005;45:89–118.
    OpenUrlCrossRefPubMed
  38. 38.↵
    1. Danesh FR,
    2. Kanwar YS
    . Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy. FASEB J 2004;18:805–15.
    OpenUrlAbstract/FREE Full Text
  39. 39.↵
    1. Nagila A,
    2. Permpongpaiboon T,
    3. Tantrarongroj S
    . Effect of atorvastatin on paraoxonase 1 (PON1) and oxidative status. Pharmacol Rep 2009;61:892–8.
    OpenUrlPubMed
  40. 40.↵
    1. Schäffler A,
    2. Ehling E,
    3. Neumann H,
    4. Herfarth H,
    5. Tarner I,
    6. Schölmerich J,
    7. et al.
    Adipocytokines in synovial fluid. JAMA 2003;290:1709–10.
    OpenUrlCrossRefPubMed
  41. 41.↵
    1. Senolt L,
    2. Housa D,
    3. Vernerová Z,
    4. Jirásek T,
    5. Svobodová R,
    6. Veigl D,
    7. et al.
    Resistin in rheumatoid arthritis synovial tissue, synovial fluid and serum. Ann Rheum Dis 2007;66:458–63.
    OpenUrlAbstract/FREE Full Text
  42. 42.↵
    1. Shyu K,
    2. Chua S,
    3. Wang B,
    4. Kuan P
    . Mechanism of inhibitory effect of atorvastatin on resistin expression induced by tumor necrosis factor-α in macrophages. J Biomed Sci 2009;16:50.
    OpenUrlCrossRefPubMed
  43. 43.↵
    1. Chu S,
    2. Ding W,
    3. Li K,
    4. Pang Y,
    5. Tang C
    . Plasma resistin associated with myocardium injury in patients with acute coronary syndrome. Circ J 2008;72:1249–53.
    OpenUrlCrossRefPubMed
  44. 44.↵
    1. Senolt L,
    2. Pavelka K,
    3. Housa D,
    4. Haluzík M
    . Increased adiponectin is negatively linked to the local inflammatory process in patients with rheumatoid arthritis. Cytokine 2006;35:247–52.
    OpenUrlCrossRefPubMed
  45. 45.↵
    1. Otero M,
    2. Lago R,
    3. Gomez R,
    4. Lago F,
    5. Dieguez C,
    6. Gómez-Reino JJ,
    7. et al.
    Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:1198–201.
    OpenUrlAbstract/FREE Full Text
  46. 46.↵
    1. Nakamura T,
    2. Kodama Y,
    3. Takano H,
    4. Umetani K,
    5. Fujioka D,
    6. Saito Y,
    7. et al.
    Increase in circulating levels of adiponectin after treatment with statin and fibrate in patients with coronary artery disease and hyperlipidemia. Atherosclerosis 2007;193:449–51.
    OpenUrlCrossRefPubMed
  47. 47.↵
    1. Koh KK,
    2. Quon MJ,
    3. Han SH,
    4. Lee Y,
    5. Kim SJ,
    6. Park JB,
    7. et al.
    Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. Atherosclerosis 2009;204:483–90.
    OpenUrlCrossRefPubMed
  48. 48.↵
    1. Bruun JM,
    2. Lihn AS,
    3. Verdich C,
    4. Pedersen SB,
    5. Toubro S,
    6. Astrup A,
    7. et al.
    Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab 2003;285:527–33.
    OpenUrl
  49. 49.↵
    1. Osei K,
    2. Gaillard T,
    3. Cook C,
    4. Kaplow J,
    5. Bullock M,
    6. Schuster D
    . Discrepancies in the regulation of plasma adiponectin and TNF-alpha levels and adipose tissue gene expression in obese African Americans with glucose intolerance: a pilot study using rosiglitazone. Ethn Dis 2005;15:641–8.
    OpenUrlPubMed
  50. 50.↵
    1. Tomas JP,
    2. Moya JL,
    3. Campuzano R,
    4. Barrios V,
    5. Megías A,
    6. Ruiz S,
    7. et al.
    Noninvasive assessment of the effect of atorvastatin on coronary microvasculature and endothelial function in patients with dyslipidemia. Rev Esp Cardiol 2004;57:909–15.
    OpenUrlCrossRefPubMed
  51. 51.↵
    1. Mäki-Petäjä KM,
    2. Booth AD,
    3. Hall FC,
    4. Wallace SML,
    5. Brown J,
    6. McEniery CM,
    7. et al.
    Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J Am Coll Cardiol 2007;50:852–8.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 38, Issue 2
1 Feb 2011
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Effect of Atorvastatin on Inflammation and Modification of Vascular Risk Factors in Rheumatoid Arthritis
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Effect of Atorvastatin on Inflammation and Modification of Vascular Risk Factors in Rheumatoid Arthritis
AMAL M. EL-BARBARY, MANAL S. HUSSEIN, ELSAYED M. RAGEH, HALA E. HAMOUDA, AYMAN A. WAGIH, RAGHDA G. ISMAIL
The Journal of Rheumatology Feb 2011, 38 (2) 229-235; DOI: 10.3899/jrheum.100582

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Effect of Atorvastatin on Inflammation and Modification of Vascular Risk Factors in Rheumatoid Arthritis
AMAL M. EL-BARBARY, MANAL S. HUSSEIN, ELSAYED M. RAGEH, HALA E. HAMOUDA, AYMAN A. WAGIH, RAGHDA G. ISMAIL
The Journal of Rheumatology Feb 2011, 38 (2) 229-235; DOI: 10.3899/jrheum.100582
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Save to my folders

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • REFERENCES
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Hospitalized Infections in People With Osteoarthritis: A National US Study
  • Axial Articular Manifestations in Primary Sjögren Syndrome: Association With Spondyloarthritis
  • Feminization of the Rheumatology Workforce: A Longitudinal Evaluation of Patient Volumes, Practice Sizes, and Physician Remuneration
Show more Articles

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2016 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire